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Abstract: Background: Tetrabenazine is the only US Food and Drug Administration-approved drug for
Huntington’s disease, and deutetrabenazine was recently tested against placebo. A switching-trial from
tetrabenazine to deutetrabenazine is underway, but no head-to-head, blinded, randomized controlled trial is
planned. Using meta-analytical methodology, the authors compared these molecules.
Methods: RCTs comparing tetrabenazine or deutetrabenazine with placebo in Huntington’s disease were
searched. The authors assessed the Cochrane risk-of-bias tool, calculated indirect treatment comparisons,
and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.
Results: The evidence network for this report comprised 1 tetrabenazine trial and 1 deutetrabenazine trial,
both against placebo. Risk of bias was moderate in both. Participants in the tetrabenazine and
deutetrabenazine trials did not differ signiﬁcantly on motor scores or adverse events. Depression and
somnolence scales signiﬁcantly favored deutetrabenazine.
Conclusion: There is low-quality evidence that tetrabenazine and deutetrabenazine do not differ in efﬁcacy or
safety. It is important to note that these results are likely to remain the only head-to-head comparison
between these 2 compounds in Huntington’s disease.
Huntington’s disease (HD) is a hereditary neurodegenerative
condition characterized by progressive motor, cognitive, and
behavioral dysfunction.1 Tetrabenazine (TBZ) is the only US
Food and Drug Administration-approved drug for chorea in
HD, and is usually taken 3 times daily. Although it was devel-
oped to treat psychosis, it was later found to ease hyperkinetic
movement disorders, including chorea, tics, tardive dyskinesia,
and dystonia, although, in the United States, it is licensed only
for treating chorea.2 Unlike classical neuroleptics, this com-
pound depletes presynaptic dopamine by blocking vesicular
monoamine transporter type 2 (VMAT2).3 Deutetrabenazine
(DEU), a structurally related molecule with deuterium (a heavy
hydrogen isotype) placed at key positions, was recently tested
successfully against placebo.4 Deuteration prolongs half-life,
reduces metabolism variability, and is proposed to translate into
less frequent dosing, a lower daily dose, and improved tolerabil-
ity. The FIRST-HD study (clinicaltrials.gov identifier
NCT01795859) has been interpreted as offering support for
similar efficacy of DEU with respect to TBZ, but with fewer
adverse effects and easier dosing.5 An unmasked switching
design trial from TBZ to DEU (ARC-HD; clinicaltrials.gov
identifier NCT01897896) is underway, but no head-to-head,
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blinded, randomized trial is planned. Therefore, we set out to
compare TBZ and DEU indirectly using meta-analysis
methodology.
Materials and Methods
Our study protocol was registered (PROSPERO
CRD42016049199) following the PRISMA-NMA framework.6
We included randomized controlled trials that compared TBZ
or DEU with placebo in patients with HD. The following out-
come domains were studied: motor, depression, somnolence,
and adverse events (AEs). Severe AEs (SAEs) were classified
according to the primary studies, although neither reported a
formal definition of an SAE. References were searched in the
MEDLINE, Embase, an SAE and CENTRAL databases, the
combining (Huntington) with (tetrabenazine OR deutetra-
benazine) and applying the Cochrane Highly Sensitive Search
Strategy for identifying randomized trials. Studies were evalu-
ated using the Cochrane risk-of-bias tool. Study selection, data
collection, and appraisal were done independently in duplicate.
Continuous and dichotomous variables were presented as mean
differences (MDs) and odds ratios, respectively, both with 95%
confidence intervals (95% CIs). Indirect treatment comparison
meta-analyses between TBZ and DEU were calculated based
on a common comparator using the Butcher method.7
Confidence in cumulative evidence was assessed using the Grad-
ing of Recommendations Assessment, Development, and Evalua-
tion (GRADE) Working Group guidelines.8 These comprise a
widely endorsed tool to assess the quality of studies contributing to
meta-research that takes into account the domains: risk of bias,
inconsistency, indirectness, imprecision, and publication bias, and
classifies evidence from high to very low quality, as follows:
•High quality: We are very confident that the true effect lies
close to that of the estimate of the effect;
•Moderate quality: We are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially differ-
ent;
•Low quality: Our confidence in the effect estimate is limited;
the true effect may be substantially different from the estimate
of the effect; and
•Very low quality: We have very little confidence in the effect
estimate; the true effect is likely to be substantially different
from the estimate of effect.
A sample-size calculation for a 1:1, parallel equivalence trial
was calculated using Stata 14.0 software (Austin, Texas) assum-
ing 80% power, 10% dropout, 0.05 alpha, a standard deviation
of 3.5 points on the Unified Huntington’s Disease Rating Scale
(UHDRS) chorea subscale score, and 20% margin of equiva-
lence of TBZ effect (5 UHDRS chorea score points).9
Results
In total, 131 references were retrieved, and 2 studies were
included.4,9 Our evidence network, describing how the
included studies related to one another, comprised 1 trial that
tested TBZ (TETRA-HD; n = 84) and another that tested
DEU (FIRST-HD; n = 90), both against placebo (Fig. 1A).
The overall risk of bias was moderate in both studies because of
attrition and reporting bias (Fig. 1B). In the TBZ arm of
TETRA-HD, proportionally more participants withdrew from
the study than in the placebo arm; and, in both studies, several
important outcome measures, such as quality of life, were miss-
ing. In other respects (random sequence generation, allocation
concealment, blinding of patient and participants, blinding of
outcome assessments, and incomplete outcome data for the
DEU trial), the studies were at low risk of bias.
After a detailed review of the methodologies and trial popu-
lations, we considered that the included studies were method-
ologically and clinically similar and comparable on effect
modifiers, confirming the transitivity assumption needed to cal-
culate an unbiased, indirect estimate of TBZ versus DEU.
Both TBZ and DEU had a mild effect on chorea versus pla-
cebo (5.0 and 4.4 point improvement in the UHDRS chorea
score, respectively) and did not differ significantly on UHDRS
the chorea score (MD 1.00; 95% CI 3.04, 1.04) or the total
motor score (MD 0.70; 95% CI 3.72, 5.12) (Table 1).
Depression and somnolence, which were evaluated using rating
scales, favored DEU significantly over TBZ in both clinical
domains (MD 0.94; 95% CI 0.88–1.00; and MD 2.10; 95% CI
0.08–4.12, respectively) (Table 1). The odds of specific AEs did
not differ significantly between interventions (Table 2). The
required sample size calculated for a 1:1, parallel, head-to-head
equivalence trial of TBZ versus DEU was 608 participants.
Discussion
Our indirect comparison, as assessed according to the GRADE
framework, shows that there is low-quality evidence that TBZ
and DEU do not differ in efficacy and safety. DEU appears sig-
nificantly less prone to depressive symptoms and somnolence,
but this observation, which was drawn from indirect analysis of
a restricted evidence network, requires validation in a direct,
suitably designed trial.
Our analysis must be interpreted with caution overall,
because indirect comparisons only provide observational evi-
dence: the power of hypothesis testing relies on between-study
heterogeneity, which thankfully was minimal in this case. Fur-
thermore, the power of our computation is limited by the evi-
dence network sample size.10
If DEU receives licensing authorization, then long-term,
phase 4 studies and real-world practice will provide further
information on the clinical utility of DEU. Nonetheless, our
analysis raises concerns for informed clinical decision making in
HD: no clinical trial has recruited over 600 participants; and, to
our knowledge, only 1 ongoing trial seeks to compare TBZ
and DEU directly: ARC-HD, whose nonrandomized, open-
label, switching design carries a risk of selection, detection, and
performance bias. Therefore, the present study seems likely to
remain the only feasible and realistic, blinded, head-to-head
comparison between TBZ and DEU in HD.
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Figure 1 A: Indirect comparison model and (B) the risk of bias in source studies. With 1 or 2 of 6 domains at high risk of bias, the over-
all risk of bias for each of these studies was classiﬁed as moderate. TBZ, tetrabenazine; DEU, deutetrabenazine.
TABLE 1 Outcomes for direct and indirect comparisons
Outcome Mean difference (95% CI)
Direct comparisonsa Indirect comparisonsb
TBZ-placebo DEU-placebo TBZ-DEU
UHDRS chorea score 3.5 (5.2, 1.9)c 2.5 (3.7, 1.3)d 1.00 (3.04, 1.04)
UHDRS total motor score 3.3 (7.0, 0.3) 4.0 (6.5, 1.5)d 0.70 (3.72, 5.12)
Depression scale 0.76 (0.71, 0.81)e 0.18 (0.22, 0.14)d 0.94 (0.88, 1.00)d
Epworth Sleepiness Scale 1.8 (0.3, 3.4)e 0.3 (1.6, 1.0)d 2.10 (0.08, 4.12)d
CI, conﬁdence interval; TBZ, tetrabenazine; DEU, deutetrabenazine; UHDRS, Uniﬁed Huntington’s Disease Rating Scale.
aFor direct comparisons, the values presented are the difference between active treatment and placebo in the mean change in score
reported in each individual study. In each case, positive values are in favor of placebo, and negative values are in favor of active treatment.
bFor indirect comparisons, the values represent the difference between TBZ and DEU in the mean change in score. Here, positive values are
in favor of DEU, and negative values are in favor of TBZ. In the TBZ study, UHDRS chorea scores were adjusted to baseline values and site,
and depression was summarized using the Hedges g effect size from the Hamilton Depression Scale. In the DEU study, UHDRS chorea
scores were adjusted to baseline values only, and depression was summarized using the Hedges g effect size from the Hospital and Anxiety
Depression Scale depression subscale.
cSigniﬁcantly favors TBZ.
dSigniﬁcantly favors DEU.
eSigniﬁcantly favors placebo.
TABLE 2 Adverse events for direct and indirect comparisons
Adverse event Odds ratio (95% CI)a
Direct comparisonsb Indirect comparisonsc
TBZ-placebo DEU-placebo TBZ-DEU
Serious adverse events,
as deﬁned by study authors
5.44 (0.28, 104.49) 1.00 (0.06, 16.50) 5.44 (0.09, 322.08)
Somnolence 13.32 (1.67, 106.07)d 2.69 (0.49, 14.64) 4.95 (0.34, 72.37)
Diarrhea 0.72 (0.15, 3.46) 9.87 (0.52, 188.88) 0.07 (0.03, 2.06)
Insomnia 21.84 (1.25, 380.62)d 1.54 (0.24, 9.66) 14.18 (0.47, 426.77)
Fatigue 1.86 (0.54, 6.37) 1.54 (0.24, 9.66) 1.21 (0.31, 11.14)
Falls 1.30 (0.36, 4.64) 0.48 (0.08, 2.74) 2.71 (0.31, 23.98)
Depression 11.15 (0.62, 200.33) 0.65 (0.10, 4.10) 17.15 (0.55, 531.90)
CI, conﬁdence interval; TBZ, tetrabenazine; DEU, deutetrabenazine.
aAll values are risk ratios with 95% CIs in parentheses, with 1 indicating absence of difference. CIs not spanning 1 indicate a statistically sig-
niﬁcantly altered odds.
bFor direct comparisons, values greater than 1 indicate an increased odds in the active treatment arm.
cFor indirect comparisons, values greater than 1 indicate an increased odds for TBZ.
dSigniﬁcantly favors placebo.
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